Overview

Denileukine Diftitox for Relapsed ALCL

Status:
Withdrawn
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine is Denileukin diftitox will be safe, well tolerated and induce a significant overall response alone and in combination with chemotherapy: ifosfamide, carboplatin and etoposide (ICE) and will be safe and well tolerated in a population of children, adolescents and young adults with relapsed or refractory anaplastic large cell lymphoma (ALCL).
Phase:
Phase 2
Details
Lead Sponsor:
Columbia University
Treatments:
Cyclophosphamide
Denileukin diftitox
Etoposide
Etoposide phosphate
Ifosfamide
Interleukin-2
Isophosphamide mustard